CoDiagnostics Appoints Maxim Group to Enhance CoSara Diagnostics Joint Venture Strategy

Co-Diagnostics Explores Strategic Path for Indian Joint Venture CoSara Diagnostics

Co-Diagnostics, Inc. announces a significant strategic development as it appoints Maxim Group LLC as its exclusive financial advisor to evaluate options for its Indian joint venture, CoSara Diagnostics Pvt. Ltd. This initiative, revealed on November 5, 2025, aligns with the company's commitment to enhancing the value of its investments and capitalizing on growth opportunities within the molecular diagnostics sector. CEO Dwight Egan expresses optimism about the collaboration with Maxim, emphasizing the goal of unlocking value for CoSara and its shareholders while adhering to the venture's founding principles.

CoSara Diagnostics, established in 2017 as a partnership between Co-Diagnostics and Synbiotics Ltd., aims to manufacture and distribute molecular diagnostics products primarily in India and expand into international markets. The joint venture is strategically positioned to leverage the growing demand for advanced diagnostic solutions in a region where healthcare access is critical. By exploring potential mergers, including with a Special Purpose Acquisition Company (SPAC), Co-Diagnostics seeks to enhance CoSara's operational capabilities and market footprint. This move reflects a broader trend within the industry where companies aim to align their resources and expertise to navigate the evolving landscape of healthcare diagnostics.

Co-Diagnostics continues to focus on developing its proprietary technologies, including the Co-Dx PCR platform, which is currently under regulatory review. This platform, designed for at-home and point-of-care testing, represents a significant advancement in the molecular diagnostics field, allowing for rapid and accurate detection of diseases. As the company works with Maxim Group, it aims to position CoSara for future growth, navigating the complexities of the market while remaining committed to its vision of providing innovative diagnostic solutions.

In addition to its strategic initiatives, Co-Diagnostics is keenly aware of the inherent risks and uncertainties associated with forward-looking statements regarding its operations and product development. The engagement with Maxim Group is part of a broader strategy to ensure that CoSara remains competitive in the rapidly evolving landscape of molecular diagnostics. As the company seeks to maximize its investments and leverage its joint venture's capabilities, it remains focused on its mission to deliver advanced diagnostic technologies that meet the growing needs of healthcare systems worldwide.